IIC
MDGL icon

Integrated Investment Consultants’s Madrigal Pharmaceuticals MDGL Stock Holding History

Integrated Investment Consultants’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$297K Buy
568
+1
+0.2% +$478 0.06% 196
2025
Q4 		$330K Hold
567
– – 0.06% 194
2025
Q3 		$260K Buy
+567
New +$212K 0.04% 272
2018
Q2 		– Sell
-57
Closed -$7K – 490
2018
Q1 		$7K Buy
+57
New +$7.04K ﹤0.01% 694

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Integrated Investment Consultants's MDGL Position: Q1 2026 in Review

Integrated Investment Consultants increased its Madrigal Pharmaceuticals (MDGL) stake by 0.18% in Q1 2026, buying an estimated $478 and bringing the position to 568 shares worth $297K. The position accounts for 0.06% of the portfolio, ranked #196.

Integrated Investment Consultants first reported a position in MDGL in Q1 2018 and has held it in 4 quarters since. The position peaked at $330K in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Integrated Investment Consultants held 568 shares of Madrigal Pharmaceuticals worth $297K as of Q1 2026.
  • Integrated Investment Consultants bought 1 Madrigal Pharmaceuticals share in Q1 2026, an estimated $478.
  • Madrigal Pharmaceuticals made up 0.06% of Integrated Investment Consultants's portfolio in Q1 2026, its #196 holding.
  • Integrated Investment Consultants first reported a position in Madrigal Pharmaceuticals in Q1 2018 and has held it in 4 quarters since.
  • Integrated Investment Consultants's Madrigal Pharmaceuticals position peaked at $330K in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Integrated Investment Consultants's 13F filing for Q1 2026, filed 1 Jun 2026.